Albany, NY (PRWEB) February 05, 2015

The research report segments the global stem cells market on the basis of type, therapeutic area, and technology. By type, stem cells are divided into embryonic stem cells, cord blood stem cells, adult stem cells, and others. By therapeutic application area, the stem cells market is categorized into orthopedics, diabetes, cardiology, hepatology, neurology, hematology, oncology, and dermatology. On the basis of technology, cord blood banking, xenotransplantation, stem cell transplantation, and CB genomics are the main sub segments. The research report studies each segment and offers unbiased and in-depth analyses of each. Key profitable areas and slow-growth segments are highlighted and discussed, and recommendations for improvement are offered.

View Full Report at http://www.marketresearchreports.biz/analysis/227569

Geographically, the stem cells market is categorized into four primary regions: North America, Europe, Asia-Pacific, and Rest of the World. The report provides global market estimations as well as predictions for each region till 2020. With the help of graphical representations, the report offers the industry shares and investment figures for individual geographic regions within the stem cells market.

While discussing the U.S. market for stem cells as part of the larger North America market, the report talks about the role and contribution of the National Institutes of Health (NIH), backing from the U.S. government for stem cell research, human embryonic stem cells development and its setbacks, the first FDA-approved human clinical trial of stem cell therapy, and issues regarding NIH funding with respect to embryonic stem cell research. The report also provides an exhaustive list of stem cell banks in the U.S.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/227569

The research report divides the Europe stem cells market into Spain, Germany, Sweden, United Kingdom, Russia, France, Switzerland, and Rest of Europe. The list of embryonic stem cell banks, cord blood stem cell banks, and adult stem cell banks are presented in a graphical format and market figures for the years 2010 and 2015, and estimations for 2020 are provided.

Segmenting the Asia-Pacific stem cells market into India, China, Australia, Japan, South Korea, and Rest of Asia-Pacific, the report discusses the stem cells sector, identifying key industry leaders. The South Korea market for stem cells is particularly highlighted, owing to the presence of many stem cell banks and drugs and continuing support from the President. The stem cell drugs and banks profiled in the research report are KRIBB, CARTISTEM, Chaum Life Center, National Stem Cell Bank, and Hearticellgram-AMI. CARTISTEM the first approved stem cell drug in the world for degenerative arthritis enjoys special mention in the research report.

The Rest of the World region includes the Middle East, Latin America, and South Africa and the research report lists out the major players operating within the stem cells market.

About MarketResearchReports.biz:

Originally posted here:
Rise in Research Funding to Aid the Stem Cells Market over the Next Five Years

Massachusetts Institute of Technology (MIT) researchers have engineered a way to use human liver cells, derived from induced pluripotent stem cells, to screen potential antimalarial drugs and vaccines for their ability to treat the liver stage of malaria infection. The approach may offer new opportunities for personalized antimalarial drug testing and the development of more effective individually tailored drugs to combat the disease, which causes more than 500,000 deaths worldwide each year.

The researchers present their work in the February 5th issue of Stem Cell Reports, the official journal of the International Society for Stem Cell Research.

"Our platform can be used for testing candidate drugs that act against the parasite in the early liver stages, before it causes disease in the blood and spreads back to the mosquito vector," says senior study author Sangeeta Bhatia, MD, PhD, the director of MIT's Laboratory for Multiscale Regenerative Technologies and a biomedical engineer at Brigham and Women's Hospital. "This is especially important given the increasing occurrence of drug-resistant strains of malaria in the field."

Malaria is caused by parasites that spread between humans through the bites of infected mosquitoes. In humans, the parasites grow and multiply first in liver cells and then in red blood cells where they cause the physical symptoms of the disease. One major challenge to malaria eradication is that the parasites can persist in the liver and cause relapses by invading the bloodstream weeks or even years later. Drugs or vaccines that target the liver stage could block the initial round of blood infection or perhaps even eradicate the dormant parasite pool and prevent relapse.

However, current methods for modeling liver-stage malaria in a dish are limited by the small available pool of liver cells from human donors and the lack of genetic diversity of these donor cells. These challenges have made it difficult not only to determine how genetics influences responses to antimalarial drugs, but also to establish a method to explore the development of personalized drugs for individual patients.

To overcome these hurdles, Bhatia and her team reprogrammed human skin cells into induced pluripotent stem cells (iPSCs)--embryonic-like stem cells capable of turning into other specific cell types relevant for studying a particular disease. iPSCs are a potentially renewable source of liver cells that retain the donor's genetic makeup and can be generated from any human donor. These features allow a broad spectrum of the human population to be represented in drug screens and provide the opportunity to test individualized responses to antimalarial drugs as well as genetic factors that determine susceptibility to infection.

The researchers infected iPSC-derived liver cells with various malaria parasites to model liver-stage malaria in the lab. These cells were sensitive to an antimalarial drug called atovaquone; chemical maturation through exposure to small molecules also made the cells sensitive to another antimalarial drug called primaquine, demonstrating the value of this approach for testing new antimalarial drugs.

"Moving forward, we hope to adapt the iPSC-derived liver cells to scalable, high-throughput culture formats to support fast, efficient antimalarial drug screens," says lead study author Shengyong Ng, a postdoctoral researcher in Bhatia's lab. "The use of iPSC-derived liver cells to model liver-stage malaria in a dish opens the door to study the influence of host genetics on antimalarial drug efficacy and lays the foundation for their use in antimalarial drug discovery."

Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.

See original here:
Malaria-in-a-dish paves the way for better treatments

Whether or not infertility can be treated with stem cells has been a matter of debate for many years.

The classical theory is based on the idea that the eggs a woman has are the ones she has had from birth, but there are researchers who claim that stem cell research could lead to the creation of new eggs. If so, this would mean that infertile women, such as those who have entered the menopause, could be given new eggs.

New studies done by researchers at the University of Gothenburg and Karolinska Institute now show that the dream of successfully treating infertility with stem cells will probably not be realized. These new research studies have been published in the journal Proceedings of the National Academy of Sciences (PNAS).

"Ever since 2004, the studies on stem cell research and infertility have been surrounded by hype. There has been a great amount of media interest in this, and the message has been that the treatment of infertility with stem cells is about to happen. However, many researchers, including my research group, have tried to replicate these studies and not succeeded. This creates uncertainty about whether it is at all possible to create new eggs with the help of stem cells," says Kui Liu, a researcher at the Department of Chemistry and Molecular Biology at the University of Gothenburg.

Together with Outi Hovatta's research group at Karolinska Institute and Jan-ke Gustafsson's research team at the University of Houston in the United States, staff at Professor Liu's laboratory have carried out experiments on mice showing that the only eggs female mice have are the ones they have from birth.

"This shows not only that the use of stem cell research in the clinical treatment of childlessness is unrealistic but also that clinics should focus on using the eggs that women have had since birth in treating infertility," says Professor Kui Liu.

Dr. Kui Liu is a Professor at the Department of Chemistry and Molecular Biology at the University of Gothenburg. His group specialises in the study of the genetic and epigenetic regulation of female germ cell development. Research in recent years has covered both preclinical basic research and the transfer of the results generated from studies of mouse models to clinically applicable techniques for treating female infertility.

Story Source:

The above story is based on materials provided by University of Gothenburg. The original article was written by Carina Eliasson. Note: Materials may be edited for content and length.

The rest is here:
Researchers question treatment of infertility with stem cells